Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials.
Palmerini T, Kirtane AJ, Serruys PW, Smits PC, Kedhi E, Kereiakes D, Sangiorgi D, Bacchi Reggiani L, Kaiser C, Kim HS, De Waha A, Ribichini F, Stone GW. Palmerini T, et al. Among authors: de waha a. Circ Cardiovasc Interv. 2012 Jun;5(3):357-64. doi: 10.1161/CIRCINTERVENTIONS.111.967083. Epub 2012 Jun 5. Circ Cardiovasc Interv. 2012. PMID: 22668554 Review.
Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.
Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, Kimura T, Briguori C, Sabatè M, Kim HS, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW. Palmerini T, et al. Among authors: de waha a. Lancet. 2012 Apr 14;379(9824):1393-402. doi: 10.1016/S0140-6736(12)60324-9. Epub 2012 Mar 23. Lancet. 2012. PMID: 22445239 Review.
Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials.
Stefanini GG, Byrne RA, Serruys PW, de Waha A, Meier B, Massberg S, Jüni P, Schömig A, Windecker S, Kastrati A. Stefanini GG, et al. Among authors: de waha a. Eur Heart J. 2012 May;33(10):1214-22. doi: 10.1093/eurheartj/ehs086. Epub 2012 Mar 24. Eur Heart J. 2012. PMID: 22447805 Free article.
Long-term outcomes of biodegradable versus durable polymer drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of individual patient data from three randomised trials.
de Waha A, King LA, Stefanini GG, Byrne RA, Serruys PW, Meier B, Jüni P, Kastrati A, Windecker S. de Waha A, et al. EuroIntervention. 2015 Apr;10(12):1425-31. doi: 10.4244/EIJV10I12A247. EuroIntervention. 2015. PMID: 24602961 Free article.
Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials.
Baber U, Mehran R, Sharma SK, Brar S, Yu J, Suh JW, Kim HS, Park SJ, Kastrati A, de Waha A, Krishnan P, Moreno P, Sweeny J, Kim MC, Suleman J, Pyo R, Wiley J, Kovacic J, Kini AS, Dangas GD. Baber U, et al. Among authors: de waha a. J Am Coll Cardiol. 2011 Oct 4;58(15):1569-77. doi: 10.1016/j.jacc.2011.06.049. Epub 2011 Sep 14. J Am Coll Cardiol. 2011. PMID: 21924575 Free article.
Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial.
Kufner S, Byrne RA, de Waha A, Schulz S, Joner M, Laugwitz KL, Kastrati A; Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2, (ISAR-DESIRE 2) Investigators. Kufner S, et al. Among authors: de waha a. Cardiovasc Revasc Med. 2014 Mar;15(2):69-75. doi: 10.1016/j.carrev.2014.02.001. Epub 2014 Feb 15. Cardiovasc Revasc Med. 2014. PMID: 24684757 Clinical Trial.
33 results